Nanomaterials public meeting
This article was originally published in The Tan Sheet
FDA will conduct a public meeting Sept. 8 to discuss regulated products that may contain nanoscale materials and request public comment on how to implement the recommendations of the Nanotechnology Task Force Report, according to an Aug. 7 Federal Register notice. In the notice, the agency asks for comment on proper assessment tools to evaluate nanomaterials, manufacturing processes for products containing nanomaterials and for personal accounts of experiences with nanoscale materials. Comments are due Oct. 24. The Nanotechnology Task Force issued its recommendations to FDA in July 2007 (1"The Tan Sheet" July 30, 2007, p. 12)...
You may also be interested in...
Rather than draft a potentially "onerous rule" based on insufficient current information about the use of nanotechnology in dietary supplements, OTC drugs and other products, FDA needs additional safety data to determine if guidance is even necessary, a leading industry scientist says
Dietary supplement industry groups say an FDA panel's report citing the lack of information about working with nanotechnology should prompt the agency to be cautious about acting on the panel's recommendation to issue a guidance on using nano-materials in new dietary ingredients
Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.